ALK and non-small cell lung carcinoma: For example, administration of monoclonal antibodies such as cetuximab, currently used to treat colorectal cancers expressing the EGFR gene [20], as well as tyrosine kinase inhibitors such as crizotinib, which is used for the treatment of non-small cell lung cancers (NSCLC) that are positive for ALK fusions [21], have been dynamically integrated into oncology practice.